Elsevier LogoRare Diseases

    ThisiscontentfromClinicalKey

    Narcolepsy

    Sign up for your free ClinicalKey trial today!  Your first step in getting the right answers when you need them.

    Start Free Trial
    Apr.11.2022

    Narcolepsy

    Synopsis

    Key Points

    • Narcolepsy is an incurable sleep disorder characterized by excessive daytime sleepiness that may be associated with cataplexy, hypnagogic hallucination, or sleep paralysis
    • Diagnostic criteria include:
      • Clinical manifestation of cataplexy and daily excessive sleepiness lasting longer than 3 months r1
      • Multiple sleep latency test showing sleep latency of 8 minutes or less and 2 or more periods of sleep-onset rapid eye movement r2
      • Cerebral spinal fluid orexin A level of 110 pg/mL or less r3
    • Treatment of excessive daytime sleepiness includes improved sleep hygiene and use of short 15-minute naps during the day; most patients will require the addition of central nervous system stimulants (eg, modafinil, methylphenidate, amphetamines) or sodium oxybate (γ-aminobutyric acid receptor agonist)
    • Treatment of cataplexy includes antidepressants (eg, venlafaxine, fluoxetine, clomipramine) or sodium oxybate
    • Antidepressants also used to suppress severe hypnagogic hallucinations and sleep paralysis
    • There is no cure for narcolepsy; however, symptoms can be improved with drug therapy and good sleep hygiene r4

    Pitfalls

    • Historically overdiagnosed owing to a dependence on the multiple sleep latency test, which has high false-positive—and false-negative—rates for diagnosis r2
      • Consider both clinical history and other tests (eg, orexin A) to reliably diagnose

    Terminology

    Clinical Clarification

    • Narcolepsy is a sleep disorder characterized by excessive daytime sleepiness associated with at least 1 of the following: r2
      • Cataplexy
      • Orexin A (hypocretin-1) deficiency in cerebrospinal fluid
      • Rapid eye movement sleep latency (time from start of sleep to onset of rapid eye movement) of 15 minutes or less
    • Some variants of narcolepsy are associated with hypnagogic or hypnopompic hallucinations or sleep paralysis

    Classification

    • Type 1 narcolepsy (60%-70% of cases)r2
      • Presence of cataplexy (transient loss of motor tone triggered by emotions; generally bilateral and brief, lasting less than 2 minutes) r1
      • Associated with cerebrospinal fluid orexin A deficiencyr1(less than 10% of patients with cataplexy have orexin A levels within reference range)r5
    • Type 2 narcolepsy (unknown prevalence)
      • Absence of cataplexy r1
      • Associated with cerebrospinal fluid orexin A levels within reference range (only 10%-15% of patients have low orexin A levels) r1
    • Secondary narcolepsy due to medical condition (often present with cataplexy) r2
      • Prader-Willi syndrome
      • Niemann-Pick disease, type C
      • Multiple sclerosis
      • Hypothalamic lesion
      • Post–head trauma
      • Postencephalitis
    • Unspecified narcolepsy r6

    Diagnosis

    Clinical Presentation

    History

    • Daily excessive daytime sleepiness for at least 3 months, associated with: r1c1
      • Frequent short naps (5-15 minutes) during daytime, usually refreshing and associated with dreams r1c2
      • Sudden, brief sleep episodes (ie, sleep attacks) during stimulating situations (eg, driving, walking, talking) c3
        • Sleep attacks are generally longer in children, up to 2 to 3 hours r7
      • Nocturnal insomnia r2c4
    • Presence of cataplexy r1c5
      • Characterized by transient loss of motor tone triggered by strong emotions (eg, joy, amusement)
        • May affect all muscles (except diaphragm and extraocular muscles) or be segmental, affecting the face, speech muscles, or limbs
        • Generally bilateral; consciousness is preserved
      • Duration of seconds to minutes
      • Associated with type 1 narcolepsy
      • Occurs in 60% to 70% of patients r2
    • Presence of hypnagogic or hypnopompic hallucinations r1c6c7c8c9
      • Vivid sensory images that occur at sleep onset (hypnagogic) or awakening (hypnopompic)
      • Hallucinations can be visual, auditory, or tactile
      • Occur in 30% to 60% of type 1 narcolepsy patients and 15% of type 2 narcolepsy patients r1
    • Sleep paralysis r1c10c11
      • Transient inability to move or speak at sleep onset
      • Lasts seconds to minutes
      • Occurs in 50% of type 1 narcolepsy patients r1
        • Sleep paralysis prevalence is unknown in type 2 narcolepsy patients

    Physical examination

    • Physical examination of patients with suspected narcolepsy is unremarkable and no objective findings assist in diagnosing the disorder; however, during cataplectic episodes, deep tendon reflexes are diminished or absent r1c12c13

    Causes and Risk Factors

    Causes c14

    • May be caused by autoimmune destruction of orexin A neurons in the brain, particularly the lateral hypothalamus r1
      • Orexin A is a neuropeptide involved in regulation of wakefulness, arousal, and appetite
      • Orexin A in cerebrospinal fluid level of 110 pg/mL or less, or less than one-third of control values, is common in patients with narcolepsy r8c15

    Risk factors and/or associations

    Age
    • Although onset ranges from early childhood to age 60 years, it peaks in patients aged 15 to 36 years r2c16
    Genetics
    • Family history of narcolepsy c17
      • Increased relative risk (10- to 40-fold) of type 1 narcolepsy is found in first-degree relatives of narcolepsy patients r1
      • HLA-DQB1*06:02 haplotype is associated with development of narcolepsy r2
        • 98% of patients with narcolepsy with cataplexy possess this haplotype r1c18
        • 25% of the general population possesses this haplotype r1
        • 40% to 60% of patients with narcolepsy without cataplexy possess this haplotype r1

    Diagnostic Procedures

    Primary diagnostic tools

    • Diagnosis is based on the clinical manifestation of excessive daytime sleepiness, a polysomnogram followed by multiple sleep latency test, and presence or absence of cataplexy r8c19c20
      • Diagnosis is confirmed with cerebrospinal fluid orexin A measurement, obtained via lumbar puncture
    • HLA typing can be obtained for further supportive evidence (when present) for narcolepsy, and it is particularly useful in children owing to its relative noninvasiveness; however, HLA results are no longer included in diagnostic criteria
    • Historically overdiagnosed owing to a dependence on the multiple sleep latency test, which has high false-positive (and false-negative) rates for diagnosis r2
      • Consider both clinical history and other tests (eg, orexin A test) to reliably diagnose

    Laboratory

    • Orexin A level of 110 pg/mL or less, or below one-third of control values—obtained via lumbar puncture—is indicative of type 1 narcolepsy r9c21
    • Obtain HLA typing, particularly in children
      • Positive finding of HLA-DQB1*06:02 haplotype is supportive of a narcolepsy diagnosis, but it is not diagnostic because it lacks specificity r2

    Functional testing

    • Polysomnographyr10 and multiple sleep latency testr11c22c23
      • Indicated for all adult patients and children aged 6 years and olderr7 with signs and symptoms suggestive of narcolepsy according to clinical presentation r1
        • Discontinue any sedating or stimulatory medications 2 weeks before the test to avoid inaccurate results (ie, washout) r11
        • Demonstrate a regular sleep-wake cycle by maintaining a sleep diary or by using actigraphy (measurement of activity and rest by a small, worn sensor) during that time r1
        • At least 6 hours of nocturnal sleep are necessary before performing the test r11
      • Overnight polysomnogram (of at least 6 hours) helps to exclude other causes of night sleep disruption (eg, sleep apnea, periodic limb movement disorder) r1
      • Next day multiple sleep latency test can measure the ability to sleep reflected by sleep latency during 20-minute nap opportunities (5 nap opportunities at 2-hour intervals), including the following 2 parameters: r11
        • Mean sleep latency: arithmetic mean of all naps or nap opportunities
        • Number of sleep-onset rapid eye movement periods during naps
      • Continuous 24-hour polysomnogram is performed in toddlers and children younger than 6 years r7
      • Results
        • Sleep latency of 8 minutes or less and 2 or more sleep-onset rapid eye movement periods are diagnostic of narcolepsy r1
          • Diagnostic specificity of multiple sleep latency test is 60%; when 2 or more sleep-onset rapid eye movement periods are present, diagnostic specificity increases to 95%
        • High false-positive and false-negative rates for diagnosis r2
          • Among patients without narcolepsy, 6% of males and 1.5% of females have test results that are diagnostic for this condition r2
          • 6% of patients with sleep-disordered breathing and 4% of patients with other sleep disorders test positive on the multiple sleep latency test r2
          • Some patients with orexin A deficiency and diagnosis of narcolepsy with cataplexy have normal multiple sleep latency test results r2
          • Underlies the importance of interpreting multiple sleep latency test results within the clinical context

    Procedures

    Lumbar puncture r1c24
    General explanation
    • Insertion of a hollow-bore needle between the vertebral bodies into the subarachnoid space to obtain a specimen of cerebrospinal fluid
    • Cerebrospinal fluid orexin A level is measured using a radioimmunoassay
    Indication
    • To collect and examine cerebrospinal fluid for diagnostic clarity when the multiple sleep latency test is not available or feasible (recommended, but not required)
    Contraindications
    • Uncontrolled coagulopathy
    • Skin infection at site of needle insertion
    • Patient at risk of brain herniation r12
      • Best predictors of precipitating herniation (even with normal CT result) include:
        • Deteriorating level of consciousness (particularly to a Glasgow Coma Scale score of 11 or less)
        • Brainstem signs (eg, pupillary changes, abnormal posturing, irregular respirations)
        • Very recent seizure
    Complications
    • Post–dural puncture headache
    • Back pain
    • Radicular injury
    • Infection
      • Epidural abscess
      • Meningitis
      • Diskitis
      • Vertebral osteomyelitis
    • Epidural hematoma
    • Cerebral herniation
    • Epidermoid tumor formation
    Interpretation of results
    • Orexin A level of 110 pg/mL or less is indicative of type 1 narcolepsy r3

    Differential Diagnosis

    Most common

    • Disorders with excessive daytime sleepiness
      • Idiopathic hypersomnia r13c25
        • Like narcolepsy, patient complains of excessive sleep
          • 10 or more hours of nighttime sleep plus daytime naps (total sleep time typically does not exceed 12 hours on weekdays, but may be as long as 19 hours on weekends or holidays) r13
        • Differentiate from narcolepsy by:
          • Lack of restive naps during the day
          • Prolonged sleep
          • Diagnosis established through a series of sleep studies
            • Epworth sleepiness scale r14
              • For a diagnosis of idiopathic hypersomnia, symptoms have to be present for 3 months or longer r13
            • Overnight polysomnogram
              • Differentiates idiopathic hypersomnia from narcolepsy and other sleep disturbances (eg, obstructive sleep apnea, periodic leg movement disorder)
            • Multiple sleep latency test r11
              • Less than 2 sleep-onset rapid eye movement periods r13
              • Mean sleep latency of 8 minutes or less
      • Sleep apnea c26
        • 1 or more pauses in breathing or shallow breaths during sleep
          • Breathing pauses can last from a few seconds to minutes and may occur 30 times or more per hour r15
          • Typically, normal breathing resumes, sometimes with a loud snort or choking sound
          • Sleep quality is poor, which results in excessive daytime sleepiness with frequent episodes of falling asleep, similar to narcolepsy
        • Differentiate from narcolepsy by history of pause in breathing during sleep, detected by polysomnography with apnea-hypopnea index of 5 or more (ie, number of apnea or hypopnea episodes per hour) r16
      • Advanced sleep phase syndrome c27c28
        • Circadian rhythm disorder defined by a stable sleep schedule that is several hours earlier than the desired sleep schedule, to the degree that the patient experiences significant difficulty keeping to a desired sleep schedule
        • Patients with advanced sleep phase syndrome are sleepy; they retire to bed early in the evening and wake up early in the morning. Sleep attacks are not reported
        • Differentiate by history of very early awakening associated with early bedtime and, if needed, polysomnography to exclude narcolepsy r17
      • Delayed sleep phase syndrome
        • Most prevalent circadian rhythm disorder; defined by delayed onset of sleep beyond the conventional bedtime, associated with difficulty in awakening at the desired time
        • Results in daytime sleepiness due to sleep deprivation; sleep attacks are not reported
        • Differentiate by history of late bedtime associated with difficulty arising at a desired (typically more conventional) time and, if needed, polysomnography to exclude narcolepsy
      • Depression with excessive daytime sleepiness c29d1
        • Disruption or irregularity in the circadian sleep-wake cycle resulting in excessive sleepiness or wakefulness at inappropriate times of day or night
        • Sleep attacks are not reported
        • Occurs in patients with depressive disorders and usually responds well to treatment of depression
        • Differentiate by history of depression and response to treatment of depression; if needed, perform multiple sleep latency test to exclude narcolepsy r1
      • Restless leg syndrome or periodic limb movement during sleep with subsequent excessive sleepiness c30
        • Irresistible urge to move the legs to avoid uncomfortable sensations, resulting in sleep disruption
        • Most patients with restless leg syndrome also have periodic limb movement during sleep, which results in nighttime awakening and daytime sleepiness
        • Sleep attacks are not reported
        • Differentiate from narcolepsy by history of restless legs when trying to sleep or periodic limb movements that disrupt sleep and multiple sleep latency test to exclude narcolepsy r1
    • Disorders with cataplexy
      • Cataplexy-like episodes in sleepy or nonsleepy patients (without narcolepsy) c31
        • Differentiate by involvement of only the lower limbs, triggered by positive and negative emotions r1
      • Cataplexy-like episodes in psychiatric patients c32
        • Differentiate by: r1
          • Prolonged duration
          • Unusual triggers and circumstances
          • Psychiatric history

    Treatment

    Goals

    • Minimize or eliminate excessive daytime sleepiness r18
    • Minimize or eliminate cataplectic episodes r18

    Disposition

    Recommendations for specialist referral

    • Refer to pediatric neurologist when narcolepsy is suspected in children, especially those younger than 6 years, owing to the difficulty in making the diagnosis
    • Neurologic consultation is recommended when the diagnosis is unclear and assistance is needed for medication management

    Treatment Options

    First step in treating narcolepsy is to provide guidance about appropriate sleep hygiene r2

    Some patients may prefer to manage without medication and may be able to adjust nap schedules that allow reasonable control r2

    • Limit naps to approximately 15 minutes
    • In prepubertal and pubertal children, at least 2 naps (lunchtime and between 4:00 and 5:00 PM) are recommended r7

    Most patients are managed with drug therapy r18

    • Central nervous system stimulants
      • Those frequently used include: r19
        • Modafinil
          • First line treatment for patients with excessive daytime sleepiness of mild to moderate degree
          • May also be used in combination with amphetamines if needed to control daytime sleepiness r2
        • Armodafinil
          • Indicated to improve wakefulness in adult patients with excessive daytime sleepiness
        • Solriamfetol r20
          • Indicated to improve wakefulness in adult patients with excessive daytime sleepiness
        • Methylphenidate r21
          • Indicated in patients with daytime sleepiness when modafinil or armodafinil is insufficient
        • Amphetamines r21
          • Indicated in patients with daytime sleepiness when other medications are ineffective
      • Tolerance can develop with use of stimulant medications; switching between drugs or scheduling drug holidays can be effective in avoiding tolerance r2
    • γ-aminobutyric acid receptor agonist
      • Sodium oxybate r19
        • Treatment for adult patients with cataplexy and useful in patients with moderate to severe daytime sleepiness
        • Highly effectiver22, although stimulants may still be required to treat daytime sleepiness r2
        • Only available through a restricted distribution program (eg, Xyrem Risk Evaluation and Mitigation Strategy programr23) owing to the need to monitor for abuse or misuse and respiratory depression that may be increased by interacting substances (eg, sedatives)
    • Pitolisant
      • First-in-class antagonist/inverse agonist of the histamine 3 receptor r24
      • FDA-approved for treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy r25
    • Antidepressants r18
      • Effective to decrease the incidence of cataplexy; also used to suppress hypnagogic hallucinations and sleep paralysis if severe
        • Venlafaxine
        • Fluoxetine
        • Clomipramine
    • The American Academy of Sleep Medicine suggests that modafinil and sodium oxybate can be used for treatment of narcolepsy in pediatric patients r6

    A 2021 Guideline from the European Academy of Neurology, the European Sleep Research Society, and the European Narcolepsy Network is available r26

    Drug therapy

    • Stimulant medication is prescribed as first line drug therapy to decrease daytime sleepiness and improve symptoms in a large majority of patients r27
    • Treatment of excessive daytime sleepiness r19
      • Wake-promoting agent
        • Modafinil r19c33
          • Typically provided as first line alternative to central nervous system stimulants
          • Modafinil Oral tablet; Children: Initially, 50 mg PO once or twice daily depending on age and weight. If needed, may increase, but do not exceed 200 to 400 mg/day. r28
          • Modafinil Oral tablet; Adolescents 17 years and older: 200 mg PO once daily as a single dose in the morning. While doses up to 400 mg PO once daily have been well tolerated, there is no consistent evidence that doses greater than 200 mg/day confer additional clinical benefit. Max: 400 mg/day PO.
          • Modafinil Oral tablet; Adults, including Geriatric Adults: 200 mg PO once daily as a single dose in the morning. While doses up to 400 mg PO once daily have been well tolerated, there is no consistent evidence that doses greater than 200 mg/day confer additional clinical benefit. Max: 400 mg/day PO.
        • Armodafinil
          • Armodafinil Oral tablet; Adults, including Geriatric Adults: 150 mg to 250 mg PO once daily as a single dose in the morning. In geriatric adults, use lowest effective dose due to the possibility of adverse effects from decreased drug elimination.
        • Solriamfetol r20r29
          • Dopamine and norepinephrine reuptake inhibitor
          • Solriamfetol Oral tablet; Adults: Initially, 75 mg PO once daily upon awakening. If needed, may increase to 150 mg PO once daily after at least 3 days. Max: 150 mg/day. Consider the use of lower doses and close monitoring in those likely to have decreased renal function, such as the geriatric adult.
      • Central nervous system stimulants r27c34
        • Methylphenidate c35
          • Given in daily divided doses
            • Therapy is initiated with immediate-release formulation until an effective daily dose is determined, then total daily dose is converted to a sustained-release formulation
          • Use caution when prescribing to patients with history of drug dependence or cardiac diseases r21c36c37
          • Methylphenidate Hydrochloride Oral tablet; Children and Adolescents 6 years and older: 5 mg PO twice daily before breakfast and lunch. Increase by 5 to 10 mg/day at weekly intervals. Max: 60 mg/day.
          • Methylphenidate Hydrochloride Oral tablet; Adults: Average dose 20 to 30 mg/day; range 10 to 60 mg/day PO in 2 to 3 divided doses, 30 to 45 minutes before meals.
        • Amphetamines c38
          • Dextroamphetamine
            • Dextroamphetamine Sulfate Oral tablet; Children 6 to 11 years: 5 mg PO once daily in the morning. May titrate daily dose by 5 mg increments at weekly intervals. Max: 60 mg/day. Use minimum effective dose.
            • Dextroamphetamine Sulfate Oral tablet; Adults, Adolescents, and Children 12 years and older: Initially, 10 mg PO once daily in the morning. May titrate by 10 mg increments at weekly intervals to the minimum effective dose. Daily dose may be given in 1 to 3 divided doses at 4 to 6 hour intervals. Avoid late evening doses. Reduce dose if anorexia or insomnia occur. Usual dosage range: 5 to 60 mg/day PO, given in divided doses. Max: 60 mg/day PO.
          • Amphetamine-dextroamphetamine
            • Amphetamine Aspartate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Oral tablet; Children 6 to 11 years: 5 mg PO once daily in the morning. Titrate by 5 mg increments at weekly intervals to minimum effective dose. Daily dose may be given in 1 to 3 divided doses at 4 to 6 hour intervals. Max: 60 mg/day.
            • Amphetamine Aspartate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Oral tablet; Adults, Adolescents, and Children 12 years and older: Initially, 10 mg PO once daily. Titrate by no more than 10 mg/day at weekly intervals to the minimum effective dose. Max: 60 mg/day PO.
    • Treatment of excessive daytime sleepiness and cataplexy r26
      • γ-aminobutyric acid receptor agonist c39
        • Sodium oxybate r19r30c40
          • Central nervous system depressant
          • Administer orally daily, increasing dose every 4 weeks; may take 8 to 12 weeks to have optimal effect r19
          • Prescribing requires enrollment in the Xyrem Risk Evaluation and Mitigation Strategy program;r23 information is available from a pharmacist
          • Patients treated with sodium oxybate should not actively experience obstructive sleep apnea or should be fully adherent to nasal CPAP device therapy
          • Sodium Oxybate (Gamma Hydroxybutyrate Or Ghb) Oral solution; Children and Adolescents 7 to 17 years weighing less than 20 kg: Specific dosing recommendations are not available; consider a lower starting dosage, lower weekly dosage increases, and lower total maximum dosage. For patients weighing 20 to 29 kg, the initial dosage is 2 grams or less/night PO, divided into 2 equal doses, the first given at bedtime and the second given 2.5 to 4 hours later. May increase dosage by no more than 1 gram/night (0.5 gram/dose) at weekly intervals. Max: 6 grams/night. For patients who sleep more than 8 hours/night, the first dose can be given at bedtime or after an initial period of sleep. Unequal dosages may be required for some patients to achieve optimal treatment.
          • Sodium Oxybate (Gamma Hydroxybutyrate Or Ghb) Oral solution; Children and Adolescents 7 to 17 years weighing 20 to 29 kg: 2 grams or less/night PO initially, divided into 2 equal doses, the first given at bedtime and the second given 2.5 to 4 hours later. May increase dosage by no more than 1 gram/night (0.5 gram/dose) at weekly intervals. Max: 6 grams/night. For patients who sleep more than 8 hours/night, the first dose can be given at bedtime or after an initial period of sleep. Unequal dosages may be required for some patients to achieve optimal treatment.
          • Sodium Oxybate (Gamma Hydroxybutyrate Or Ghb) Oral solution; Children and Adolescents 7 to 17 years weighing 30 to 44 kg: 3 grams or less/night PO initially, divided into 2 equal doses, the first given at bedtime and the second given 2.5 to 4 hours later. May increase dosage by no more than 1 gram/night (0.5 gram/dose) at weekly intervals. Max: 7.5 grams/night. For patients who sleep more than 8 hours/night, the first dose can be given at bedtime or after an initial period of sleep. Unequal dosages may be required for some patients to achieve optimal treatment.
          • Sodium Oxybate (Gamma Hydroxybutyrate Or Ghb) Oral solution; Children and Adolescents 7 to 17 years weighing 45 kg or more: 4.5 grams or less/night PO initially, divided into 2 equal doses, the first given at bedtime and the second given 2.5 to 4 hours later. May increase dosage by no more than 1.5 grams/night (0.75 grams/dose) at weekly intervals. Max: 9 grams/night. For patients who sleep more than 8 hours/night, the first dose can be given at bedtime or after an initial period of sleep. Unequal dosages may be required for some patients to achieve optimal treatment.
          • Sodium Oxybate (Gamma Hydroxybutyrate Or Ghb) Oral solution; Adults: 4.5 grams/night PO initially, divided into 2 equal doses of 2.25 grams, the first given at bedtime and the second given 2.5 to 4 hours later. May increase dosage by 1.5 grams/night (0.75 grams/dose) at weekly intervals. Effective dosage range: 6 to 9 grams/night. Doses more than 9 grams/night have not been studied and should not ordinarily be administered.
      • Pitolisant r24r25
        • First and only medication not categorized as a controlled substance that is FDA-approved for treatment of symptoms of narcolepsy r25
        • Pitolisant Oral tablet; Adults: 8.9 mg PO once daily in the morning upon awakening for 1 week. Then, increase to 17.8 mg PO once daily for 1 week. After that, adjust to efficacy and tolerability. Max: 35.6 mg/day PO; limit to 17.8 mg/day PO in CYP2D6 poor metabolizers. Coadministration of certain drugs may need to be avoided or dosage adjustments may be necessary; review drug interactions.
    • Treatment of cataplexy, severe hypnagogic hallucinations, or severe sleep paralysis r2
      • Venlafaxine r31c41c42c43
        • Off-label indication
        • Venlafaxine Hydrochloride Oral tablet, extended-release; Adults: Initially, 75 mg PO once daily. If needed, may increase further by 75 mg/day at intervals of no less than every 4 days. Max: 225 mg/day.
      • Fluoxetine r31c44c45c46
        • Off-label indication
        • Fluoxetine Hydrochloride Oral capsule; Adults: 20 mg/day PO initially. May increase the dose every month by 10 to 20 mg if needed. Max: 80 mg/day. May divide into 2 doses if dosage is 20 mg/day or more, given at morning and at noon.
      • Clomipramine r31c47c48c49
        • Off-label indication
        • Clomipramine Hydrochloride Oral capsule; Adults: Initially, 25 mg PO once daily, may gradually increase in the first 2 weeks to 100 mg/day PO, given in divided doses. Max: 250 mg/day. After titration, the total daily dose may be given at bedtime to minimize daytime sedation.

    Nondrug and supportive care

    • Counsel patients to improve sleep hygiene r2c50
      • Maintain regular sleep schedule to get adequate sleep (most patients require 7-9 hoursr32)
      • Schedule regular naps throughout the day to improve alertness r26
      • Allow 1-hour period before bedtime for relaxation r32
    • Avoid stimuli (eg, alcohol, heavy meals) that promote sleep attacks r18c51c52
    • Avoid stimulants (eg, caffeine, nicotine) 6 hours before bedtime r32
    • Engage in regular exercise to promote wakefulness (but not close to bedtime) r18c53

    Comorbidities

    • Sleep disorders, such as sleep apnea r26
      • Should be treated as in non-narcoleptic patients

    Special populations

    • Pregnant and/or breastfeeding women
      • Consider potential risks of medical therapy for narcolepsy along with potential benefits. No teratogenicity has been shown, but none of the drugs typically used for narcolepsy have been specifically studied r4
        • If a patient being treated becomes pregnant, can reassure her about the absence of teratogenic effects associated with central nervous system stimulants, antidepressants, or sodium oxybate. May withdraw medications during pregnancy as further caution
          • For those maintained on medical therapy during pregnancy, consideration is given to temporarily discontinue some or all of the drugs used near delivery due to their possible effects on the newborn (eg, sedation, withdrawal)
        • For women who want to become pregnant, either stop medication before pregnancy occurs or monitor closely for pregnancy and stop medical therapy with first positive pregnancy test
        • Because all the medications employed in narcolepsy pass into breast milk, patient should feed baby formula if she wants to continue or resume medical therapy after delivery

    Monitoring

    • Regular monitoring is required to determine the effectiveness of therapy and identify any adverse effects
      • Monitor sleepiness and subjective response to medication using an objective measure, such as the Epworth Sleepiness Scale r31
      • Once stabilized on a stimulant or other medication, monitor for sleep disturbances, cardiovascular or metabolic abnormalities, and mood changes
    • Because there is a risk of respiratory depression for those being treated with sodium oxybate, patients prescribed this medication must be monitored for obstructive sleep apnea or must adhere to nasal CPAP device therapy r33
      • If obstructive sleep apnea is not present initially, monitor with nocturnal oximetry for its development:
        • Every 2 years for all patients treated with sodium oxybate
        • Annually for obese patients (with BMI greater than 30)
        • After a 6.8-kg weight gain
        • After an increase in snoring (as indicated by the visual analog snoring severity scale)
        • After initiating a new sedating medication (which may worsen obstructive sleep apnea)

    Complications and Prognosis

    Complications

    • Increased incidence of accidents owing to daytime sleepiness c54
    • Difficulty with professional and interpersonal relationships owing to daytime sleepiness c55c56

    Prognosis

    • There is no cure for narcolepsy; however, symptoms can improve approximately 80% with drug therapy and good sleep hygiene r4
      • Patient must make adjustments to manage wakefulness and sleepiness and maintain regularity in sleep/wake patterns r4
      • Follow medication closely

    Screening and Prevention

    Screening c57

    Prevention c58

    Iranzo A: Current diagnostic criteria for adult narcolepsy. In: Baumann CR et al, eds: Narcolepsy Pathophysiology, Diagnosis, and Treatment. Springer; 2011:369-81Leschziner G: Narcolepsy: a clinical review. Pract Neurol. 14(5):323-31, 201424830461Mignot E et al: The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol. 59(10):1553-62, 200212374492Mignot EJ: A practical guide to the therapy of narcolepsy and hypersomnia syndromes. Neurotherapeutics. 9(4):739-52, 201223065655Thorpy MJ: Classification of sleep disorders. Neurotherapeutics. 9(4):687-701, 201222976557Maski K et al: Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 17(9):1881-1893, 202134743789Nevsimalova S: The diagnosis and treatment of pediatric narcolepsy. Curr Neurol Neurosci Rep. 14(8):469, 201424954623Sateia MJ: International classification of sleep disorders-third edition: highlights and modifications. Chest. 146(5):1387-94, 201425367475Heier MS et al: CSF hypocretin-1 levels and clinical profiles in narcolepsy and idiopathic CNS hypersomnia in Norway. Sleep. 30(8):969-73, 200717702265Kushida CA et al: Practice parameters for the indications for polysomnography and related procedures: an update for 2005. Sleep. 28(4):499-521, 200516171294Krahn LE et al: Recommended protocols for the Multiple Sleep Latency Test and Maintenance of Wakefulness Test in adults: guidance from the American Academy of Sleep Medicine. J Clin Sleep Med. 17(12):2489-2498, 202134423768Joffe AR: Lumbar puncture and brain herniation in acute bacterial meningitis: a review. J Intensive Care Med. 22(4):194-207, 200717712055Dauvilliers Y et al: Idiopathic hypersomnia. In: Kryger M et al, eds: Principles and Practice of Sleep Medicine. 6th ed. PA: Elsevier; 2017:883-91Johns MW: A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 14(6):540-5, 19911798888Ferri FF: Sleep apnea, obstructive. In: Ferri FF, ed: Ferri's Clinical Advisor 2016. Elsevier; 2016:1139-40Greenberg H et al: Obstructive sleep apnea. In: Kryger M et al, eds: Principles and Practice of Sleep Medicine. 6th ed. Elsevier; 2017:1110-24Tsai SC: The history and physical examination of the sleep patient. In: Kirsch DB, ed: Sleep Medicine in Neurology. John Wiley & Sons; 2014:8-20Madala RR et al: Approach to a patient with narcolepsy. In: Kirsch DB, ed: Sleep Medicine in Neurology. John Wiley & Sons; 2014:43-50Billiard M et al: Management of narcolepsy in adults. In: Gilhus NE et al, eds: European Handbook of Neurological Management. 2nd ed. Blackwell Publishing; 2011:513-28Wang J et al: Efficacy and safety of solriamfetol for excessive sleepiness in narcolepsy and obstructive sleep apnea: findings from randomized controlled trials. Sleep Med. 79:40-47, 202133472129Wise MS et al: Treatment of narcolepsy and other hypersomnias of central origin. Sleep. 30(12):1712-27, 200718246981Xu XM et al: Gamma-hydroxybutyrate (GHB) for narcolepsy in adults: an updated systematic review and meta-analysis. Sleep Med. 64:62-70, 201931671326Jazz Pharmaceuticals: The XYREM REMS program: an overview. XYREM website. Published 2021. Accessed December 16, 2021. https://www.xyrem.com/healthcare-professionals/xyrem-rems-program/https://www.xyrem.com/healthcare-professionals/xyrem-rems-program/Lamb YN: Pitolisant: a review in narcolepsy with or without cataplexy. CNS Drugs. 34(2):207-218, 202031997137Practical Neurology. FDA approves expanded use of pitolisant for treatment of cataplexy in adults with narcolepsy. Published October 20, 2020. Accessed December 16, 2021. https://practicalneurology.com/news/fda-approves-expanded-use-of-pitolisant-for-treatment-of-cataplexy-in-adults-with-narcolepsyhttps://practicalneurology.com/news/fda-approves-expanded-use-of-pitolisant-for-treatment-of-cataplexy-in-adults-with-narcolepsyBassetti CLA et al: European guideline and expert statements on the management of narcolepsy in adults and children. Eur J Neurol. 28(9):2815-2830, 202134173695Benbadis SR: Effective treatment of narcolepsy with codeine in a patient receiving hemodialysis. Pharmacotherapy. 16(3):463-5, 19968726607Sullivan SS: Current treatment of selected pediatric sleep disorders. Neurotherapeutics. 9(4):791-800, 201223055049Thorpy MJ et al: A randomized study of solriamfetol for excessive sleepiness in narcolepsy. Ann Neurol. 85(3):359-70, 201930694576Abad VC: An evaluation of sodium oxybate as a treatment option for narcolepsy. Expert Opin Pharmacother. 20(10):1189-99, 201931136215Scammell TE: Narcolepsy. N Engl J Med. 373(27):2654-62, 201526716917Adenuga O et al: Treatment of disorders of hypersomnolence. Curr Treat Options Neurol. 16(9):302, 201425080137Feldman NT: Clinical perspective: monitoring sodium oxybate-treated narcolepsy patients for the development of sleep-disordered breathing. Sleep Breath. 14(1):77-9, 201019626356
    Small Elsevier Logo

    Cookies are used by this site. To decline or learn more, visit our cookie notice.


    Copyright © 2024 Elsevier, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

    Small Elsevier Logo
    RELX Group